Author: Mohammad Javad Nasiri; Sara Haddadi; Azin Tahvildari; Yeganeh Farsi; Mahta Arbabi; Saba Hasanzadeh; Parnian Jamshidi; Mukunthan Murthi; Mehdi Mirsaeidi
Title: COVID-19 clinical characteristics, and sex-specific risk of mortality: Systematic Review and Meta-analysis Document date: 2020_3_26
ID: bsz2lda6_45
Snippet: The most prevalent comorbidities in our study were hypertension (18.5 %, CI 12.7-24.4) followed 307 by cardiovascular diseases (14.9 %, CI 6.0-23.8) and diabetes (10.8 %, CI 8.3-13.3). According 308 to a systematic review for comorbidities by Yang et al, hypertension (17 ± 7%, CI 14-22%) and 309 diabetes (8 ± 6%, CI 6-11%), followed by cardiovascular diseases (5 ± 4%, CI 4-7%) were the 310 most common comorbid findings (11) . The high prevalen.....
Document: The most prevalent comorbidities in our study were hypertension (18.5 %, CI 12.7-24.4) followed 307 by cardiovascular diseases (14.9 %, CI 6.0-23.8) and diabetes (10.8 %, CI 8.3-13.3). According 308 to a systematic review for comorbidities by Yang et al, hypertension (17 ± 7%, CI 14-22%) and 309 diabetes (8 ± 6%, CI 6-11%), followed by cardiovascular diseases (5 ± 4%, CI 4-7%) were the 310 most common comorbid findings (11) . The high prevalence of hypertension and other 311 cardiovascular comorbidities have raised speculation regarding the role of angiotensin-converting 312 enzyme Inhibitors (ACEI) in COVID-19. Angiotensin-converting enzyme 2 (ACE2) receptor has 313 been identified as the receptor used by SARS-CoV-2 to infect human cells and previous studies 314 have shown that the usage of ACEI results in the upregulation of ACE2 (12) (13) . Theoretically, 315 this increase in ACE2 levels could result in a greater risk of infection with the SARS-CoV-2 virus. 316 . CC-BY 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Search related documents:
Co phrase search for related documents- Angiotensin convert and SARS virus: 1, 2
- cardiovascular disease and cc international license: 1, 2, 3, 4, 5, 6, 7
- cardiovascular disease and CI diabetes: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cardiovascular disease and CI diabetes CI: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cardiovascular disease and CI diabetes CI cardiovascular disease: 1, 2, 3, 4, 5, 6
- cardiovascular disease and CI hypertension: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cardiovascular disease and great risk: 1, 2
- cardiovascular disease and high prevalence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cardiovascular disease and human cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- cardiovascular disease and hypertension high prevalence: 1, 2, 3, 4, 5, 6, 7, 8
- cardiovascular disease and international license: 1, 2, 3, 4, 5, 6, 7
- cardiovascular disease and previous study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- cardiovascular disease and SARS virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cardiovascular disease and SARS virus infection: 1, 2, 3, 4, 5, 6, 7, 8
- cc international license and human cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- cc international license and international license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cc international license and previous study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- cc international license and SARS virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cc international license and SARS virus infection: 1, 2
Co phrase search for related documents, hyperlinks ordered by date